Unknown

Dataset Information

0

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.


ABSTRACT: The lipoate derivative CPI-613 is a first-in-class agent that targets mitochondrial metabolism. This study determined the effects of CPI-613 on mitochondrial function and defined the MTD, pharmacokinetics, and safety in patients with relapsed or refractory hematologic malignancies.Human leukemia cell lines were exposed to CPI-613 and mitochondrial function was assayed. A phase I trial was conducted in which CPI-613 was given as a 2-hour infusion on days 1 and 4 for 3 weeks every 28 days.CPI-613 inhibited mitochondrial respiration of human leukemia cells consistent with the proposed mechanism of action. In the phase I trial, 26 patients were enrolled. CPI-613 was well tolerated with no marrow suppression observed. When the infusion time was shortened to 1 hour, renal failure occurred in 2 patients. At 3,780 mg/m(2), there were two dose-limiting toxicities (DLT). At a dose of 2,940 mg/m(2) over 2 hours, no DLTs were observed, establishing this as the MTD. Renal failure occurred in a total of 4 patients and resolved in all but 1, who chose hospice care. CPI-613 has a triphasic elimination with an alpha half-life of approximately 1.34 hours. Of the 21 evaluable, heavily pretreated patients, 4 achieved an objective response and 2 achieved prolonged stabilization of disease for a clinical benefit rate of 29%. Following drug exposure, gene expression profiles of peripheral blood mononuclear cells from responders demonstrated immune activation.CPI-613 inhibits mitochondrial function and demonstrates activity in a heavily pretreated cohort of patients.

SUBMITTER: Pardee TS 

PROVIDER: S-EPMC4199870 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.

Pardee Timothy S TS   Lee King K   Luddy John J   Maturo Claudia C   Rodriguez Robert R   Isom Scott S   Miller Lance D LD   Stadelman Kristin M KM   Levitan Denise D   Hurd David D   Ellis Leslie R LR   Harrelson Robin R   Manuel Megan M   Dralle Sarah S   Lyerly Susan S   Powell Bayard L BL  

Clinical cancer research : an official journal of the American Association for Cancer Research 20140827 20


<h4>Purpose</h4>The lipoate derivative CPI-613 is a first-in-class agent that targets mitochondrial metabolism. This study determined the effects of CPI-613 on mitochondrial function and defined the MTD, pharmacokinetics, and safety in patients with relapsed or refractory hematologic malignancies.<h4>Experimental design</h4>Human leukemia cell lines were exposed to CPI-613 and mitochondrial function was assayed. A phase I trial was conducted in which CPI-613 was given as a 2-hour infusion on day  ...[more]

Similar Datasets

| S-EPMC9720358 | biostudies-literature
| S-EPMC9176802 | biostudies-literature
| S-EPMC9032382 | biostudies-literature
| S-EPMC7072383 | biostudies-literature
| S-EPMC5991736 | biostudies-literature
| S-EPMC7218437 | biostudies-literature
| S-EPMC6896080 | biostudies-literature
| S-EPMC5927637 | biostudies-literature
| S-EPMC8609999 | biostudies-literature